1h ago
Arcellx (ACLX) Jumps After Gilead's $7.8 Billion Acquisition Deal at $115 Per Share
On February 23, 2026, shares of Arcellx surged after Gilead Sciences agreed to buy the biotech company in a transaction valuing it at about $7.8 billion, including a $115 per share cash offer. The deal adds a potential $5 per share contingent value right tied to sales of Arcellx's CAR-T therapy anito-cel, while the stock price spiked to around $113.95 on heavy trading volume. The acquisition, expected to close in the second quarter of 2026, follows an existing partnership and could become accretive to Gilead's earnings after potential FDA approval.